KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Capital Leases (2019)

Adaptive Biotechnologies (ADPT) has disclosed Capital Leases for 1 consecutive years, with $36.6 million as the latest value for Q4 2019.

  • Quarterly Capital Leases changed N/A to $36.6 million in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $36.6 million through Dec 2019, changed N/A year-over-year, with the annual reading at $36.6 million for FY2019, N/A changed from the prior year.
  • Capital Leases hit $36.6 million in Q4 2019 for Adaptive Biotechnologies, up from $23.4 million in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $36.6 million in Q4 2019 to a low of $23.4 million in Q3 2019.